scispace - formally typeset
B

Baron Shopsin

Researcher at New York University

Publications -  58
Citations -  2471

Baron Shopsin is an academic researcher from New York University. The author has contributed to research in topics: Lithium (medication) & Lithium carbonate. The author has an hindex of 25, co-authored 58 publications receiving 2456 citations.

Papers
More filters
Journal ArticleDOI

Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients.

TL;DR: Hospitalized bipolar and unipolar endogenously depressed patients who showed an antidepressant response to the monoamine oxidase (MAO) inhibitor, tranylcypromine sulfate, relapsed when relatively small doses of parachlorophenylalanine (PCPA) were added for brief periods, suggesting serotonergic mechanisms are likely involved in the antidepressant effects of both the tricyclic drugs and MAO inhibitors in man.
Journal Article

Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients.

TL;DR: Urinary excretion levels of MHPG in one of the patients studied longitudinally did not correspond to the direction of clinical affective state but did reflect anticipated changes during alpha-MPT treatment, suggesting that serotonergic mechanisms are likely involved in the anti-depressant effects of imipramine in man.
Journal ArticleDOI

Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol

TL;DR: Qualitative differences between lithium carbonate and haloperidol indicate that, while haloperodol has a more dramatically rapid impact on behavior-motor activity, lithium Carbonate acted more evenly on the entire manic picture, with total normalization realized during active treatment.
Journal ArticleDOI

Lithium and leukocytosis

TL;DR: Peripheral blood specimens from 22 hospitalized psychiatric patients and one outpatient were examined for white blood cell count changes during treatment with lithium carbonate; a trend toward neutrophilia and lymphocytopenia emerged but cannot be said to account for the global change in total WBG.
Journal ArticleDOI

Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison.

TL;DR: The data suggest that clozapine in the present population of newly admitted, acutely psychotic schizophrenic individuals, and in the doses employed, was more effective in overall improvement response, discharge rate, and ameliorating discrete symptoms across the different objective rating scales used than was chlorpromazine (Thorazine) hydrochloride.